12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cx601: Phase I/II final data

Final data from an open-label, Spanish Phase I/II trial in 24 patients showed that Cx601 was safe with no treatment-related adverse events reported that indicated any clinical safety concerns at 6-month follow up. At week 24, Cx601 produced a reduction in the number of draining fistulas from baseline in 69.2% of patients. Furthermore, 56.3% of patients achieved a complete closure of the treated fistula and 30% of...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >